In a patient with a history of peripheral arterial disease and femoral artery occlusion status post superficial femoral artery angioplasty, is full-dose anticoagulation indicated?

Full-Dose Anticoagulation is NOT Indicated After SFA Angioplasty

Full-dose anticoagulation should not be used in this patient unless there is a separate indication (e.g., atrial fibrillation, venous thromboembolism). The 2024 ACC/AHA guidelines explicitly state that full-intensity oral anticoagulation in PAD patients without another indication is harmful (Class 3: Harm, Level A) 1111.

Recommended Antithrombotic Strategy Post-SFA Angioplasty

After endovascular revascularization for PAD, you have two evidence-based options:

First-Line Option (Class I, Level A):

Low-dose rivaroxaban 2.5 mg twice daily + aspirin 81-100 mg daily to reduce both major adverse cardiovascular events (MACE) and major adverse limb events (MALE) 111. This combination is superior to antiplatelet therapy alone for preventing both cardiovascular and limb complications.

Alternative Option (Class 2a, Level C-LD):

Dual antiplatelet therapy (DAPT) with clopidogrel 75 mg + aspirin 81 mg daily for 1-6 months, followed by single antiplatelet therapy 111. This is reasonable but has less robust evidence than the rivaroxaban-aspirin combination.

Key Clinical Decision Points

Assess bleeding risk first:

• If the patient has non-high bleeding risk: Use rivaroxaban 2.5 mg BID + aspirin (preferred) or DAPT for 1-6 months
• If the patient has high bleeding risk: Use single antiplatelet therapy (clopidogrel 75 mg daily preferred over aspirin) 11

After the initial 1-6 month period:

• Transition to single antiplatelet therapy (clopidogrel 75 mg daily is preferred over aspirin for MACE reduction) 111
• Consider continuing rivaroxaban + aspirin long-term if high ischemic risk and acceptable bleeding risk

Why Full-Dose Anticoagulation is Harmful

The 2024 guidelines are unequivocal: full-intensity anticoagulation (therapeutic warfarin or therapeutic-dose DOACs) increases life-threatening bleeding without reducing cardiovascular or limb events 111. A 2007 trial demonstrated that combining full-dose anticoagulation with antiplatelet therapy resulted in 3.4 times more life-threatening bleeding (4.0% vs 1.2%, P<0.001) without reducing MI, stroke, or cardiovascular death 2.

Special Circumstance: If Anticoagulation Required for Another Indication

If your patient requires full-intensity anticoagulation for atrial fibrillation, mechanical valve, or VTE:

• Use oral anticoagulant monotherapy (Class 2b recommendation) 3
• Adding single antiplatelet therapy is reasonable if not at high bleeding risk (Class 2a, Level C-LD) 11
• Do NOT use triple therapy (anticoagulant + DAPT) routinely—bleeding risk outweighs benefit

Common Pitfalls to Avoid

1. Do not confuse low-dose rivaroxaban (2.5 mg BID) with therapeutic anticoagulation—they are completely different strategies with different risk-benefit profiles
2. Do not continue DAPT indefinitely—limit to 1-6 months post-procedure unless using the rivaroxaban-aspirin combination
3. Do not use aspirin monotherapy—clopidogrel is superior for MACE reduction in PAD 11
4. Do not prescribe therapeutic anticoagulation "just to be safe"—it increases mortality risk without benefit 12